Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Omega-3-acid ethyl esters 90 may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR Omacor contains highly _ purified omega-3 polyunsaturated fatty acids.
240 mm
KNOW
BEFORE
YOU
e e
If any of the above applies to you, do not take this medicine, and talk to your doctor.
e
Talk to your doctor or pharmacist before taking Omacor. if you are due to have or have had surgery recently if you have had a trauma recently if you have a kidney problem if you have diabetes which is not controlled if you have problems with your liver. Your doctor will monitor any effects Omacor may have on your liver with blood tests. if you are allergic to fish
& = © wv
Swallow the capsules with a drink of water. You may take the capsules at meal times to help reduce gastro-intestinal side effects. Your doctor will decide how long you should take this medicine.
Dose to treat high blood triglyceride levels (high levels of fat in the blood or hypertriglyceridaemia)
& E
The usual dose is 2 capsules a day, as recommended by a doctor. If the medicine is not working well enough at this dose, your doctor may increase this to 4 capsules a day.
Warnings and precautions
e
& © wv
OMACOR Always take Omacor exactly as your doctor has told you. You should check with your doctor or 5mm pharmacist if you are not sure.
Do not take Omacor: e if you are allergic (hypersensitive) to the active substances or any of the other ingredients of Omacor (listed in Section 6: Contents of the pack and other information).
e
E
Omacor contains soya oil Omacor contains soya oil. If you are allergic to peanut or soya, do not use this medicinal product.
Omacor is used: e to treat certain forms of increased triglycerides (fats) in the blood after changes to the diet have not worked. TO
"
Driving and using machines This medicine is not likely to affect you being able to drive or use any tools or machines.
Omacor belongs to a group of so called reducers of cholesterol and triglycerides.
2. WHAT YOU NEED TAKE OMACOR
| Spot 10 x 2mm £ £
Pregnancy and breast-feeding You should not take this medicine if you are pregnant or breast-feeding, unless your doctor decides it is absolutely necessary. Ask your doctor or pharmacist for advice before using any medicine.
Oakhoa
text free area
Please tell your doctor or pharmacist if you are using, have recently used or might use any other medicines including medicines obtained without prescription.
Children Children should not take this medicine.
Nd
area reserved for laetuscode
blood
40 mm upper folded side
—-
e
blood tests and your usual dose of your thinning medicine may have to be changed.
ee 1mm
15mm
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
80 mm
Omega-3-acid ethyl esters 90
oO wT
If you take more Omacor than you should If you accidentally take more of this medicine than you should, do not worry, as this is unlikely to need special treatment. However, you should contact your doctor or pharmacist for further advice. If you forget to take Omacor
Other medicines and Omacor
oO wT
5mm
If you are using a medicine to stop blood clotting in your arteries, such as warfarin you may need extra
& E
If you miss a dose, take it when you remember unless it is almost time for your next dose, in which case take the next dose as usual. Do not take a double dose (twice the dose recommended by your doctor) to make up for a forgotten dose.
zone for text
FRONT
© viaTris Werre gC
DE CMe
Omacor, 1000 mg, 28, 100
260
Component Type feaictic.) PER
ume
STRUT
EI
TrackWise/GLAMS Job No-
3248053 2149302
I
PL 15905/0001
Nadal and PA 1099/1/1 Tye
a
ADA,
eT gM soe
rol er
eT aici aa
Page Count
aur
fe) CTT ey yi mls Colours
Ireland, United Kingdom
Barcode Info §) #7: Um
Superseded Supplier Code Ets!) by!)
P|
Ld
&
Time: 17:40
Vendor Job No. 8) F:¥
he( i 8030185
VE ome
No. of colours
Cilia
GMPack ApS (Hadsund – DK)
NLA,
STE VCR hd 4 Ti ETM ALLE
Helvetica Neue
Body Text Size Feta
TESTES
240x180mm
US
8.5 pt
Keyline/Drawing No. §, 9:3
STC TEC
V3 MAY 2023
180 mm E E
If you have any further questions on the use of this product, ask your doctor or pharmacist.
6. CONTENTS OF INFORMATION What Omacor
AND
OTHER
contains
The active substances are omega-3-acid ethyl esters, 1000 mg of omega-3-acid ethyl esters 90 comprising 460 mg eicosapentaenoic acid (EPA), 380 mg docosahexaenoic acid (DHA) ethyl esters (these substances are called omega-3 polyunsaturated fatty arnt and including also 4 . mg d-alpha-tocopherol (mixed with a vegetable . ae oil €.g. soya oil) as antioxidant. The soft capsule shell is made up of gelatine, glycerol, medium-chain triglycerides, lecithin (soya) and purified water.
Uncommon
What
side effects (occur in 1 to 10 users
pack
Omacor
looks
like and
contents
5e e
hgh blood sugar levels ear ess
Omacor capsules are transparent capsules containing pale yellow oil.
e e e e e
problems with taste headache low blood pressure nose bleed blood in your stools
Omacor
e
rash
Rare side 10,000):
effects
(occur
e e
soft
E Oo +
a
of the
E
gelatin
oO +
is available in the following pack sizes: capsules capsules capsules capsules
–
10 users
in
° allergic reactions
itchy rash (hives or urticaria) liver disorders, with possible changes inthe results of certain blood tests
Other side effects have occurred inaverysmall
240 mm
PACK
4. POSSIBLE SIDE EFFECTS Like all medicines, Omacor can cause side effects, although not everybody gets them. The following are side effects that may happen with this medicine: : : : 'on
(occur in 1 to 10 users in : abdominal ' ' ' e . stomach problems like distension, pain, constipation, diarrhoea, indigestion (dyspepsia), gas, belching (eructation), acid reflux, feeling sick (nausea) and being sick (vomiting)
in 1, ,000):
text free area
THE
Marketing
Manufacturer pasras PO. Box 420
Authorisation
Holder
and
= € 9
NO-1327 Lysaker
number of people but their exact frequency is
Norway.
See toting
Manufacturer
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
BASF AS Framnesveien 41. _NO-3222 Sandefjord Norway
Reporting of side effects
or
pierre Fabre Médicament Production
€
pharmacist. This includes any possible side effects not listed : in this . leaflet. You: can also . report side effects directly via the national reporting system. By reporting side effects you can help provide
|, Payrat FR- _ 46000 Cahors France ;
E
If you get any side effects, talk to your doctor or
5mm more information on the safety of this medicine.
–_
oO +
This leaflet was last updated: September 2023.
In the UK: The Yellow Card Scheme at:
Omacor is supplied in the UK by Viatris UK Healthcare Limited, 20 Station Close, Potters Bar,
Yellow Card in the Google Play or Apple App Store. In Ireland:
Omacor is supplied in Ireland by Mylan IRE Healthcare Limited, Newenham Court, Northern
www.mhra.gov.uk/yellowcard or search for MHRA
Hertfordshire, EN6 1TL.
Reports may be made via freepost, to the following | Cross, Malahide Road, Dublin 17, Ireland.
address:
HPRA Pharmacovigilance
® Registered Trademark
Ee
Earlsfort Terrace IRL – Dublin 2 Tel: +353 1 6764971 Fax: +353 1 6762517 Website: www.hpra.ie e-mail: [email protected]
£ oO v
OMACOR e e
ee
Keep this medicine out of the sight and reach of children. Do not use Omacor after the expiry date which is stated on the carton and the label. The expiry
date refers to the last day of the month. e
£
Donot store Omacor above 25°C. Do not freeze.
a
E
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
& VIATRIS
9
3948053
8030185
BACK
zone for text
© ViaTRis WTetrnal (iyi
Date: 22 AUG 2023
Omacor, 1000 mg, 28, 100
960
Component Type eat) PEC
Be
Ta
3248053
a 208 a00541 486
Superseded Affiliate Item Code Par Getty
MCC
NLA,
TrackWise/GLAMS Job No. BYZ5;{1G%}
rir aecme
1
ate Supplier SAP No.
(PL 15905/0001=|
[and 1099/1/1 PA | NAL A.
New Supplier Code 'go30185 Tec Ge
no
R yum eet 6030150 dig
sid
HICH ELLCaia
asco wo A sooo as
GMPack ApS (Hadsund – DK)
Ireland, United Kingdom
No. of colours
&
Time: 17:40 Page Count
Colours
a |
ie Colours
(Gaal
W497
UTE VCR bd. with
LU
Helvetica Neue
MM
240x180mm
Sl Ora
8.5 pt
Keyline/Drawing No. §) #4
TCTLE
V3 MAY 2023
Omacor 1000 mg Soft Capsules comes as capsule containing 1000mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Omacor 1000 mg Soft Capsules is omega-3-acid ethyl esters 90.
Medicines with the same active substance, strength and form include: Omega 3-acid-ethyl esters 1000mg soft capsules, Teromeg 1000 mg Capsules. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Omacor 1000 mg Soft Capsules, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Hypertriglyceridaemia
Endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response:
- type IV in monotherapy,
- type IIb/III in combination with statins, when control of triglycerides is insufficient.
Hypertriglyceridaemia
Initial treatment two capsules daily. If adequate response is not obtained, the dose may be increased to four capsules daily.
The capsules may be taken with food to avoid gastrointestinal disturbances.
There is limited clinical data regarding the use of Omacor in elderly patients over 70 years of age and patients with renal impairment (see section 4.4).
There is no information regarding the use of Omacor in children and adolescents or in patients with hepatic impairment (see section 4.4).
Hypersensitivity to the active substance, to soya or to any of the excipients listed in section 6.1.
Omacor contains soya oil. If you are allergic to peanut or soya, do not use this medicinal product.
Omacor should be used with caution in patients with known sensitivity or allergy to fish.
In the absence of efficacy and safety data, use of this medication in children is not recommended.
Clinical data regarding the use of Omacor in elderly patients over 70 years of age are limited.
Because of the moderate increase in bleeding time (with the high dosage, i.e. 4 capsules), patients receiving anticoagulant therapy must be monitored and the dosage of anticoagulant adjusted if necessary (see section 4.5 Interaction with other Medicinal Products and other forms of Interaction). Use of this medication does not eliminate the need for the surveillance usually required for patients of this type.
Make allowance for the increased bleeding time in patients at high risk of haemorrhage (because of severe trauma, surgery, etc).
During treatment with Omacor, there is a fall in thromboxane A2 production. No significant effect has been observed on the other coagulation factors. Some studies with omega-3-acids demonstrated a prolongation of bleeding time, but the bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes.
Only limited information regarding the use in patients with renal impairment is available.
In some patients a small but significant increase (within normal values) in ASAT and ALAT was reported, but there are no data indicating an increased risk for patients with hepatic impairment. ALAT and ASAT levels should be monitored in patients with any signs of liver damage (in particular with the high dosage, i.e. 4 capsules).
Omacor is not indicated in exogenous hypertriglyceridaemia (type 1 hyperchylomicronaemia). There is only limited experience in secondary endogenous hypertriglyceridaemia (especially uncontrolled diabetes).
There is no experience regarding hypertriglyceridaemia in combination with fibrates.
Oral anticoagulants: See Section 4.4 Special warnings and precautions for use.
Omacor has been given in conjunction with warfarin without haemorrhagic complications. However, the prothrombin time must be checked when Omacor is combined with warfarin or when treatment with Omacor is stopped.
Pregnancy
There are no adequate data from the use of Omacor in pregnant women.
Studies in animals have not shown reproductive toxicity. The potential risk for humans is unknown and therefore Omacor should not be used during pregnancy unless clearly necessary.
Breastfeeding
There are no data on the excretion of Omacor in animal and human milk. Omacor should not be used during lactation.
Fertility
There are no adequate data on the effect of Omacor on fertility.
Effects on ability to drive and use machines have not been studied. Nevertheless, Omacor is expected to have no or negligible influence on the ability to drive and use machines.
The frequencies of adverse reactions are ranked according to the following : very common (> 1/10), common (> 1/100 to < 1/10); uncommon (>1/1000 to < 1/100); rare (>1/10,000 to < 1/1000); very rare (< 1/10,000) ; not known
Immune system disorders:
Rare: hypersensitivity
Metabolism and nutrition disorders:
Uncommon: hyperglycaemia, gout
Nervous system disorders:
Uncommon: dizziness, dysgeusia, headache
Vascular disorders:
Uncommon: hypotension
Respiratory thoracic and mediastinal disorders:
Uncommon: epistaxis
Gastrointestinal disorders:
Common: gastrointestinal disorders (including abdominal distension, abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, eructation, gastro-oesophageal reflux disease, nausea or vomiting)
Uncommon: gastrointestinal haemorrhage
Hepatobiliary disorders:
Rare: liver disorders (including transaminases increased, alanine aminotransferase increased and aspartate aminotransferase increased)
Skin and subcutaneous tissue disorders:
Uncommon: rash
Rare: urticaria
Not known: pruritus
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There are no special recommendations. Treatment should be symptomatic.
Ask anything about Omacor 1000 mg Soft Capsules. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.